Endocannabinoid signaling in Alzheimer's disease: Current knowledge and future directions

C. D'Addario, A. Di Francesco, L. Trabace, A. Finazzi Agrò, V. Cuomo, Mauro Maccarrone

Research output: Contribution to journalArticle

Abstract

The importance of the endocannabinoid system (ECS) in the modulation functions of the central nervous system has been extensively investigated during the last few years. In particular, accumulated evidence has implicated ECS in the pathophysiology of Alzheimer's disease (AD), that is a progressive, degenerative, and irreversible disorder characterized by the accumulation in the brain of β-amyloid fragments forming insoluble plaques, and of intracellular neurofibrillary tangles (NTFs) associated with synaptic and neuronal loss. In all the processes involved in the formation of both plaques and NFTs, the key-role played by the ECS has been documented. Here, we review current knowledge and future directions of ECS modulation both in animal models of AD and in human tissues, underlying the role of endocannabinoid signaling in the development of AD hallmarks. Overall, the available data suggest that next generation therapeutics might target distinct ECS elements, for instance CB 2 receptor or fatty acid amide hydrolase, as a promising approach to halt or at least to slow down disease progression.

Original languageEnglish
Pages (from-to)61-73
Number of pages13
JournalJournal of Biological Regulators and Homeostatic Agents
Volume27
Issue number2 SUPPL.
Publication statusPublished - Apr 2013

Fingerprint

Endocannabinoids
Alzheimer Disease
Neurofibrillary Tangles
Amyloid
Disease Progression
Direction compound
Central Nervous System
Animal Models
Brain

Keywords

  • Alzheimer's disease
  • Endocannabinoid
  • Inflammation
  • Lipoxygenase
  • Neuroinflammation

ASJC Scopus subject areas

  • Oncology
  • Endocrinology, Diabetes and Metabolism
  • Physiology (medical)
  • Immunology and Allergy
  • Immunology
  • Endocrinology
  • Physiology
  • Cancer Research

Cite this

D'Addario, C., Di Francesco, A., Trabace, L., Finazzi Agrò, A., Cuomo, V., & Maccarrone, M. (2013). Endocannabinoid signaling in Alzheimer's disease: Current knowledge and future directions. Journal of Biological Regulators and Homeostatic Agents, 27(2 SUPPL.), 61-73.

Endocannabinoid signaling in Alzheimer's disease : Current knowledge and future directions. / D'Addario, C.; Di Francesco, A.; Trabace, L.; Finazzi Agrò, A.; Cuomo, V.; Maccarrone, Mauro.

In: Journal of Biological Regulators and Homeostatic Agents, Vol. 27, No. 2 SUPPL., 04.2013, p. 61-73.

Research output: Contribution to journalArticle

D'Addario, C, Di Francesco, A, Trabace, L, Finazzi Agrò, A, Cuomo, V & Maccarrone, M 2013, 'Endocannabinoid signaling in Alzheimer's disease: Current knowledge and future directions', Journal of Biological Regulators and Homeostatic Agents, vol. 27, no. 2 SUPPL., pp. 61-73.
D'Addario, C. ; Di Francesco, A. ; Trabace, L. ; Finazzi Agrò, A. ; Cuomo, V. ; Maccarrone, Mauro. / Endocannabinoid signaling in Alzheimer's disease : Current knowledge and future directions. In: Journal of Biological Regulators and Homeostatic Agents. 2013 ; Vol. 27, No. 2 SUPPL. pp. 61-73.
@article{7f24cf6aee4641849db3ad8d24531a9c,
title = "Endocannabinoid signaling in Alzheimer's disease: Current knowledge and future directions",
abstract = "The importance of the endocannabinoid system (ECS) in the modulation functions of the central nervous system has been extensively investigated during the last few years. In particular, accumulated evidence has implicated ECS in the pathophysiology of Alzheimer's disease (AD), that is a progressive, degenerative, and irreversible disorder characterized by the accumulation in the brain of β-amyloid fragments forming insoluble plaques, and of intracellular neurofibrillary tangles (NTFs) associated with synaptic and neuronal loss. In all the processes involved in the formation of both plaques and NFTs, the key-role played by the ECS has been documented. Here, we review current knowledge and future directions of ECS modulation both in animal models of AD and in human tissues, underlying the role of endocannabinoid signaling in the development of AD hallmarks. Overall, the available data suggest that next generation therapeutics might target distinct ECS elements, for instance CB 2 receptor or fatty acid amide hydrolase, as a promising approach to halt or at least to slow down disease progression.",
keywords = "Alzheimer's disease, Endocannabinoid, Inflammation, Lipoxygenase, Neuroinflammation",
author = "C. D'Addario and {Di Francesco}, A. and L. Trabace and {Finazzi Agr{\`o}}, A. and V. Cuomo and Mauro Maccarrone",
year = "2013",
month = "4",
language = "English",
volume = "27",
pages = "61--73",
journal = "Journal of Biological Regulators and Homeostatic Agents",
issn = "0393-974X",
publisher = "Biolife s.a.s.",
number = "2 SUPPL.",

}

TY - JOUR

T1 - Endocannabinoid signaling in Alzheimer's disease

T2 - Current knowledge and future directions

AU - D'Addario, C.

AU - Di Francesco, A.

AU - Trabace, L.

AU - Finazzi Agrò, A.

AU - Cuomo, V.

AU - Maccarrone, Mauro

PY - 2013/4

Y1 - 2013/4

N2 - The importance of the endocannabinoid system (ECS) in the modulation functions of the central nervous system has been extensively investigated during the last few years. In particular, accumulated evidence has implicated ECS in the pathophysiology of Alzheimer's disease (AD), that is a progressive, degenerative, and irreversible disorder characterized by the accumulation in the brain of β-amyloid fragments forming insoluble plaques, and of intracellular neurofibrillary tangles (NTFs) associated with synaptic and neuronal loss. In all the processes involved in the formation of both plaques and NFTs, the key-role played by the ECS has been documented. Here, we review current knowledge and future directions of ECS modulation both in animal models of AD and in human tissues, underlying the role of endocannabinoid signaling in the development of AD hallmarks. Overall, the available data suggest that next generation therapeutics might target distinct ECS elements, for instance CB 2 receptor or fatty acid amide hydrolase, as a promising approach to halt or at least to slow down disease progression.

AB - The importance of the endocannabinoid system (ECS) in the modulation functions of the central nervous system has been extensively investigated during the last few years. In particular, accumulated evidence has implicated ECS in the pathophysiology of Alzheimer's disease (AD), that is a progressive, degenerative, and irreversible disorder characterized by the accumulation in the brain of β-amyloid fragments forming insoluble plaques, and of intracellular neurofibrillary tangles (NTFs) associated with synaptic and neuronal loss. In all the processes involved in the formation of both plaques and NFTs, the key-role played by the ECS has been documented. Here, we review current knowledge and future directions of ECS modulation both in animal models of AD and in human tissues, underlying the role of endocannabinoid signaling in the development of AD hallmarks. Overall, the available data suggest that next generation therapeutics might target distinct ECS elements, for instance CB 2 receptor or fatty acid amide hydrolase, as a promising approach to halt or at least to slow down disease progression.

KW - Alzheimer's disease

KW - Endocannabinoid

KW - Inflammation

KW - Lipoxygenase

KW - Neuroinflammation

UR - http://www.scopus.com/inward/record.url?scp=84886781972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886781972&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84886781972

VL - 27

SP - 61

EP - 73

JO - Journal of Biological Regulators and Homeostatic Agents

JF - Journal of Biological Regulators and Homeostatic Agents

SN - 0393-974X

IS - 2 SUPPL.

ER -